SARS-CoV-2 vaccine candidate shows promise against variants

By The Science Advisory Board staff writers

May 10, 2021 -- A pancoronavirus vaccine candidate created by the Infectious Disease Research Institute (IDRI), the Duke Human Vaccine Institute, and 3M shows potential to protect against variants of SARS-CoV-2, according to a study published May 10 in Nature.

The vaccine candidate combines a Duke-developed nanoparticle with IDRI's formulation of 3M's 3M-052 compound. The study shows that it boosts production of neutralizing antibodies against several coronavirus strains.

The drug not only could protect against coronaviruses but also reduce the need for booster shots, according to Dr. Corey Casper, CEO of IDRI.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.